Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy

Abstract

Objective [¹⁷⁷Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [¹⁷⁷Lu]Lu-PSMA-617 RLT.

Materials and Methods We conducted a retrospective analysis among 27 patients (mean age: 71.0 ± 9.5 years; range: 52–85 years) who underwent PSMA PET/computed tomography (CT) and subsequent [¹⁷⁷Lu]Lu-PSMA-617 RLT between March 2019 and January 2023. After excluding patients with liver metastases, the number of patients left for analysis was 21 (14 responders and 7 nonresponders). Tumors were semiautomatically delineated with calculation of total tumor volume (PSMA-TV), lesion uptake (PSMA-TLU = PSMA-TV * standardized uptake value [SUV]mean), and lesion quotient (PSMA-TLQ = PSMA-TV/SUVmean) for each patient. Semiquantitative parameters were analyzed only in patients with mCRPC and no liver metastasis.

Results In total, 17/27 patients (62.96%) had a decline in PSA levels; 15/27 patients (55.56%) experienced a decline of > 50%. Pretherapeutic PSMA PET/CT results revealed significant differences in PSMA-TV (p = 0.003), PSMA-TLU (p = 0.013), and PSMA-TLQ (p = 0.011) between responders and nonresponders. SUVmax was significantly correlated to the best percentage change in PSA response after ¹⁷⁷Lu-PSMA-617 treatment (r = −0.79, p = 0.006). No association was observed between PSMA-TV (p = 0.367), PSMA-TLU (p = 0.128), and PSMA-TLQ (p = 0.556), with the best percentage change in PSA response after ¹⁷⁷Lu-PSMA-617 therapy.

Conclusion Pretherapeutic PSMA PET-derived PSMA-TV, PSMA-TLU, and PSMA-TLQ were significant negative predictors of PSA response in patients with mCRPC and no liver metastasis receiving [¹⁷⁷Lu]Lu-PSMA-617 RLT.

Keywords

pretherapeutic PSMA PET - metastatic castration-resistant prostate cancer - liver metastasis - [¹⁷⁷Lu]Lu-PSMA-617 - radioligand therapy

Publikationsverlauf

Artikel online veröffentlicht:
23. Februar 2024

• References

• 1 Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med 2018; 378 (07) 645-657
• 2 Nuhn P, De Bono JS, Fizazi K. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 2019; 75 (01) 88-99
• 3 Afshar-Oromieh A, Hetzheim H, Kratochwil C. et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med 2015; 56 (11) 1697-1705
• 4 Violet J, Jackson P, Ferdinandus J. et al. Dosimetry of ¹⁷⁷Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 2019; 60 (04) 517-523
• 5 Banerjee S, Pillai MRA, Knapp FFR. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 2015; 115 (08) 2934-2974
• 6 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58 (01) 85-90
• 7 Hofman MS, Violet J, Hicks RJ. et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19 (06) 825-833
• 8 Hofman MS, Emmett L, Violet J. et al; ANZUP TheraP team. TheraP: a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int 2019; 124 (Suppl. 01) 5-13
• 9 Sartor O, de Bono J, Chi KN. et al; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385 (12) 1091-1103
• 10 Manafi-Farid R, Harsini S, Saidi B. et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [¹⁷⁷Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging 2021; 48 (12) 4028-4041
• 11 Gafita A, Heck MM, Rauscher I. et al. Early prostate-specific antigen changes and clinical outcome after ¹⁷⁷Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med 2020; 61 (10) 1476-1483
• 12 Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA change after [¹⁷⁷Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival. Cancers (Basel) 2021; 14 (01) 149
• 13 Kyriakopoulos CE, Chen Y-H, Carducci MA. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018; 36 (11) 1080-1087
• 14 Sweeney CJ, Chen Y-H, Carducci M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373 (08) 737-746
• 15 Mokoala K, Lawal I, Lengana T. et al. PSMA theranostics: science and practice. Cancers (Basel) 2021; 13 (15) 3904
• 16 Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med 2020; 45 (12) 935-942
• 17 Sadaghiani MS, Sheikhbahaei S, Werner RA. et al. ¹⁷⁷Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis. Prostate 2022; 82 (07) 826-835
• 18 Khreish F, Ghazal Z, Marlowe RJ. et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging 2022; 49 (03) 1075-1085
• 19 Ahmadzadehfar H, Rahbar K, Baum RP. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [¹⁷⁷Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging 2021; 48 (01) 113-122
• 20 Halabi S, Kelly WK, Ma H. et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 2016; 34 (14) 1652-1659
• 21 Khreish F, Kochems N, Rosar F. et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging 2021; 48 (01) 103-112
• 22 Pouessel D, Gallet B, Bibeau F. et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int 2007; 99 (04) 807-811
• 23 Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2014; 2 (04) 273-285
• 24 Akfirat C, Zhang X, Ventura A. et al. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol 2013; 230 (03) 291-297
• 25 Morrissey C, True LD, Roudier MP. et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2008; 25 (04) 377-388
• 26 Seifert R, Herrmann K, Kleesiek J. et al. Semiautomatically quantified tumor volume using ⁶⁸Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med 2020; 61 (12) 1786-1792
• 27 Seifert R, Kessel K, Schlack K. et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging 2021; 48 (04) 1200-1210
• 28 Ferdinandus J, Violet J, Sandhu S. et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging 2020; 47 (10) 2322-2327
• 29 Uprimny C, Kroiss AS, Decristoforo C. et al. ⁶⁸Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44 (06) 941-949
• 30 Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T. PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under ¹⁷⁷Lu-PSMA-617 radioligand therapy. Cancers (Basel) 2021; 13 (12) 2938
• 31 Derlin T, Sommerlath Sohns JM, Schmuck S. et al. Influence of short-term dexamethasone on the efficacy of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Prostate 2020; 80 (08) 619-631